Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis
Go back to Vertex Announces Planned Initiation of Phase 2 Studies Evaluating the Next-Generation Correctors VX-440 and VX-152 in Triple Combination Regimens to Treat the Underlying Cause of Cystic Fibrosis| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 511.84 +3.50 (0.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $508.34 | 52 Week High | $134.71 | |||
| Open | $506.85 | 52 Week Low | $73.31 | |||
| Day High | $513.98 | P/E | N/A | |||
| Day Low | $501.01 | EPS | $-1.98 | |||
| Volume | 374,767 | |||||
